hydroxychloroquine and low-certainty evidence for sulfasalazine based on the amount of data supporting the disease-modifying properties of methotrexate monotherapy compared to hydroxychloroquine or sulfasalazine and concerns over the long-term tolerability of sulfasalazine Methotrexate is conditionally recommended over leflunomide for DMARD-naive patients with moderate-to-high disease activity Despite low-certainty evidence of comparable efficacy, methotrexate is preferred over leflunomide